医学
硼胆酸
脂肪肝
脂肪性肝炎
肝移植
肝硬化
内科学
肝病
人口
慢性肝病
酒精性肝病
疾病
胃肠病学
环境卫生
移植
受体
兴奋剂
作者
The Lancet Gastroenterology & Hepatology
标识
DOI:10.1016/s2468-1253(19)30429-7
摘要
A prespecified 18-month interim analysis of the REGENERATE trial, recently published in The Lancet, indicated that obeticholic acid can improve fibrosis in patients with pre-cirrhotic non-alcoholic steatohepatitis (NASH). Although phase 2 and 3 trials of novel treatments for NASH cirrhosis have largely been disappointing, a number of drugs are moving along the pipeline for non-cirrhotic NASH, with several currently in phase 3 trials for this indication. REGENERATE is the first phase 3 trial to report positive findings, and the improvements in fibrosis, together with other markers of non-alcoholic fatty liver disease (NAFLD) disease activity, are likely to be sufficient for obeticholic acid to become the first drug to receive regulatory approval for NASH.
科研通智能强力驱动
Strongly Powered by AbleSci AI